We serve Chemical Name:4-(1-Adamantyl)benzenesulfonyl chloride CAS:144174-50-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(1-Adamantyl)benzenesulfonyl chloride
CAS.NO:144174-50-5
Synonyms:f1928-0014
Molecular Formula:C16H19ClO2S
Molecular Weight:310.83900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:42.52000
Exact Mass:310.07900
LogP:5.16270
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like f1928-0014 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,f1928-0014 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,f1928-0014 Use and application,f1928-0014 technical grade,usp/ep/jp grade.
Related News: ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 4-(1-Adamantyl)benzenesulfonyl chloride manufacturer API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. 4-(1-Adamantyl)benzenesulfonyl chloride supplier ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 4-(1-Adamantyl)benzenesulfonyl chloride vendor One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. 4-(1-Adamantyl)benzenesulfonyl chloride factory API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.
